Skip to main content
Premium Trial:

Request an Annual Quote

In Case You Needed More Reason to Love Open Access

Over at evolgen, the blogger who goes by RPM links to a video interview with Michael Ashburner hosted by BioMed Central. In the interview, Ashburner is "espousing the virtues of open access," writes RPM, noting that the highly regarded scientist "also walks the walk, proclaiming that he will not publish in non-open access journal, nor review articles for non-open access journals."

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.